JP2012526544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526544A5 JP2012526544A5 JP2012510423A JP2012510423A JP2012526544A5 JP 2012526544 A5 JP2012526544 A5 JP 2012526544A5 JP 2012510423 A JP2012510423 A JP 2012510423A JP 2012510423 A JP2012510423 A JP 2012510423A JP 2012526544 A5 JP2012526544 A5 JP 2012526544A5
- Authority
- JP
- Japan
- Prior art keywords
- pde4d7
- expression
- prostate cancer
- sample
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010060862 Prostate cancer Diseases 0.000 claims 31
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 31
- 239000005556 hormone Substances 0.000 claims 30
- 229940088597 hormone Drugs 0.000 claims 30
- 230000003211 malignant effect Effects 0.000 claims 26
- 108090000623 proteins and genes Proteins 0.000 claims 26
- 239000000523 sample Substances 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 19
- 238000000034 method Methods 0.000 claims 14
- 238000012544 monitoring process Methods 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 238000003018 immunoassay Methods 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 206010004385 Benign neoplasm of prostate Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000010324 immunological assay Methods 0.000 claims 4
- 108091070501 miRNA Proteins 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 3
- 239000013068 control sample Substances 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 108091005461 Nucleic proteins Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 108700039887 Essential Genes Proteins 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 101001067140 Homo sapiens Porphobilinogen deaminase Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003281 allosteric effect Effects 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000013480 data collection Methods 0.000 claims 1
- 239000012649 demethylating agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09159960 | 2009-05-12 | ||
| EP09159960.5 | 2009-05-12 | ||
| EP09169739.1 | 2009-09-08 | ||
| EP09169739 | 2009-09-08 | ||
| PCT/IB2010/052072 WO2010131194A1 (en) | 2009-05-12 | 2010-05-11 | Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178795A Division JP6246167B2 (ja) | 2009-05-12 | 2015-09-10 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526544A JP2012526544A (ja) | 2012-11-01 |
| JP2012526544A5 true JP2012526544A5 (https=) | 2013-06-27 |
Family
ID=42352017
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510423A Pending JP2012526544A (ja) | 2009-05-12 | 2010-05-11 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2015178795A Active JP6246167B2 (ja) | 2009-05-12 | 2015-09-10 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2017092325A Active JP6588496B2 (ja) | 2009-05-12 | 2017-05-08 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2019104594A Pending JP2019205431A (ja) | 2009-05-12 | 2019-06-04 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178795A Active JP6246167B2 (ja) | 2009-05-12 | 2015-09-10 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2017092325A Active JP6588496B2 (ja) | 2009-05-12 | 2017-05-08 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2019104594A Pending JP2019205431A (ja) | 2009-05-12 | 2019-06-04 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8778621B2 (https=) |
| EP (1) | EP2430190B1 (https=) |
| JP (4) | JP2012526544A (https=) |
| KR (2) | KR20120036842A (https=) |
| CN (1) | CN102439176B (https=) |
| BR (1) | BRPI1007704A2 (https=) |
| DK (1) | DK2430190T3 (https=) |
| ES (1) | ES2707598T3 (https=) |
| WO (1) | WO2010131194A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2700877T3 (es) * | 2009-05-12 | 2019-02-19 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador de cáncer de próstata |
| ES2707598T3 (es) * | 2009-05-12 | 2019-04-04 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador para cáncer maligno de próstata sensible a hormonas |
| GB201322034D0 (en) | 2013-12-12 | 2014-01-29 | Almac Diagnostics Ltd | Prostate cancer classification |
| GB201504763D0 (en) | 2015-03-20 | 2015-05-06 | Mironid Ltd | Compounds and uses |
| RU2721916C2 (ru) * | 2015-05-29 | 2020-05-25 | Конинклейке Филипс Н.В. | Способы прогнозирования рака предстательной железы |
| WO2016193110A1 (en) | 2015-05-29 | 2016-12-08 | Koninklijke Philips N.V. | Methods of prostate cancer prognosis |
| KR101663675B1 (ko) | 2016-07-27 | 2016-10-07 | 강성훈 | 유체 흐름 유도장치 |
| GB201616439D0 (en) | 2016-09-28 | 2016-11-09 | Mironid Limited | Compounds and uses |
| RU2766885C2 (ru) * | 2016-12-01 | 2022-03-16 | Конинклейке Филипс Н.В. | Оценки риска на основе экспрессии варианта 7 фосфодиэстеразы 4d человека |
| EP3502280A1 (en) | 2017-12-21 | 2019-06-26 | Koninklijke Philips N.V. | Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables |
| EP3546598A1 (en) * | 2018-03-29 | 2019-10-02 | Koninklijke Philips N.V. | Post-surgical risk stratification based on pde4d variant expression, selected according to tmprss2-erg fusion status, and post-surgical clinical variables |
| GB201805527D0 (en) | 2018-04-04 | 2018-05-16 | Mironid Ltd | Compounds and their use as pde4 activators |
| WO2020010305A1 (en) | 2018-07-05 | 2020-01-09 | The Board Of Regents Of The University Of Oklahoma | Gene signatures for cancer characterization and methods of use |
| EP3636779A1 (en) * | 2018-10-11 | 2020-04-15 | Koninklijke Philips N.V. | Pre-surgical risk stratification based on pde4d7 and dhx9 expression |
| CN111198270B (zh) * | 2018-11-16 | 2023-04-07 | 山东泽济生物科技有限公司 | 一种用于甘油醛-3-磷酸脱氢酶磁微粒化学发光检测试剂盒及其制备方法 |
| EP4360711A1 (en) * | 2022-10-27 | 2024-05-01 | Koninklijke Philips N.V. | Treatment of prostate cancer by promoting pde4d7 |
| EP4608430A1 (en) | 2022-10-27 | 2025-09-03 | Koninklijke Philips N.V. | Treatment of prostate cancer by promoting pde4d7 |
| EP4600377A1 (en) | 2024-02-12 | 2025-08-13 | Koninklijke Philips N.V. | Prediction of an outcome of a subject suffering from a glioma |
| CN121548649A (zh) | 2023-07-18 | 2026-02-17 | 皇家飞利浦有限公司 | 预测患有神经胶质瘤的受试者的结果 |
| EP4603836A1 (en) | 2024-02-13 | 2025-08-20 | Koninklijke Philips N.V. | Prediction of an outcome of a prostate cancer subject |
| EP4620461A1 (en) | 2024-03-22 | 2025-09-24 | Koninklijke Philips N.V. | Treatment of prostate cancer by inhibiting short pde4d isoforms |
| CN118726352B (zh) * | 2024-06-28 | 2025-11-07 | 山东大学 | 启动子元件及其在3-羟基丙酸生物合成中的应用 |
| EP4722388A1 (en) | 2024-10-03 | 2026-04-08 | Koninklijke Philips N.V. | Prediction of an outcome of a subject suffering from acute myoloid leukemia |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6261562B1 (en) * | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| CN100419079C (zh) * | 1998-07-14 | 2008-09-17 | 科里克萨有限公司 | 用于治疗和诊断前列腺癌的组合物和方法 |
| IL156413A0 (en) | 2001-01-31 | 2004-01-04 | Pfizer Prod Inc | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| IS7221A (is) * | 2001-11-15 | 2004-04-15 | Memory Pharmaceuticals Corporation | Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra |
| US20030220273A1 (en) * | 2002-05-15 | 2003-11-27 | Isis Pharmaceuticals Inc. | Antisense modulation of phosphodiesterase 4D expression |
| AU2003301894A1 (en) * | 2002-11-08 | 2004-06-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) |
| CA2542656A1 (en) * | 2003-10-16 | 2005-05-06 | Genomic Health, Inc. | Qrt-pcr assay system for gene expression profiling |
| WO2006028655A2 (en) * | 2004-08-13 | 2006-03-16 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| JP4644737B2 (ja) * | 2005-05-13 | 2011-03-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ジアリールヒダントイン化合物 |
| WO2007134451A1 (en) * | 2006-05-19 | 2007-11-29 | Topigen Pharmaceuticals Inc. | Oligonucleotides affecting expression of phosphodiesterases |
| JP2009540852A (ja) * | 2006-07-03 | 2009-11-26 | エグゾニ・テラピューティック・ソシエテ・アノニム | 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用 |
| US9939441B2 (en) * | 2006-07-21 | 2018-04-10 | Epigenomics Ag | Methods and nucleic acids for analyses for cellular proliferative disorders |
| WO2009065511A2 (en) * | 2007-11-23 | 2009-05-28 | Epigenomics Ag | Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders |
| ES2700877T3 (es) * | 2009-05-12 | 2019-02-19 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador de cáncer de próstata |
| ES2707598T3 (es) * | 2009-05-12 | 2019-04-04 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador para cáncer maligno de próstata sensible a hormonas |
-
2010
- 2010-05-11 ES ES10726250T patent/ES2707598T3/es active Active
- 2010-05-11 EP EP10726250.3A patent/EP2430190B1/en active Active
- 2010-05-11 WO PCT/IB2010/052072 patent/WO2010131194A1/en not_active Ceased
- 2010-05-11 US US13/320,050 patent/US8778621B2/en active Active
- 2010-05-11 KR KR1020117029706A patent/KR20120036842A/ko not_active Ceased
- 2010-05-11 CN CN201080020794.8A patent/CN102439176B/zh active Active
- 2010-05-11 BR BRPI1007704-9A patent/BRPI1007704A2/pt not_active Application Discontinuation
- 2010-05-11 KR KR1020177037100A patent/KR102110469B1/ko active Active
- 2010-05-11 DK DK10726250.3T patent/DK2430190T3/en active
- 2010-05-11 JP JP2012510423A patent/JP2012526544A/ja active Pending
-
2015
- 2015-09-10 JP JP2015178795A patent/JP6246167B2/ja active Active
-
2017
- 2017-05-08 JP JP2017092325A patent/JP6588496B2/ja active Active
-
2019
- 2019-06-04 JP JP2019104594A patent/JP2019205431A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526544A5 (https=) | ||
| JP2017184729A5 (https=) | ||
| CN106796239B (zh) | 用于诊断胰腺癌的组合物以及使用其诊断胰腺癌的方法 | |
| JP6774925B2 (ja) | 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療のための方法並びにそのキット | |
| RU2011150279A (ru) | Фосфодиэстераза 4d7 как маркер рака предстательной железы | |
| JP5224309B2 (ja) | 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用 | |
| EP3132266B1 (en) | New biomarkers for metastatic breast cancer | |
| WO2012129325A1 (en) | Molecular analysis of tumor samples | |
| KR20170130441A (ko) | 암 진단용 바이오마커 패널 | |
| JP6983221B2 (ja) | 大腸癌の併用検査 | |
| Xu et al. | Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma | |
| US20170322216A1 (en) | Pancreatic cancer diagnostic | |
| JP2012526543A5 (https=) | ||
| WO2014198995A1 (es) | Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas | |
| RU2011150291A (ru) | Фосфодиэстераза-9а в качестве маркера злокачественной опухоли предстательной железы | |
| US20240077487A1 (en) | Method for the detection of lung cancer | |
| JP7558391B2 (ja) | バフィーコート試料に使用するための膵臓癌診断用組成物 | |
| JP2013213774A (ja) | 結核検査用バイオマーカー | |
| TW201930881A (zh) | 大腸直腸腺瘤之檢測及治療方法 | |
| JP7614477B2 (ja) | 間質性肺炎のタンパク質診断バイオマーカー | |
| JP6691337B2 (ja) | 膀胱癌患者の予後を予測するための方法 | |
| Kim et al. | Combined Application of CEA, CA 15-3, and CA 27-29 for the Evaluation of Diagnostic Performance in Canine Mammary Gland Tumors | |
| US20240241130A1 (en) | Biomarker for predicting response to immune checkpoint inhibitor | |
| EP2876442A1 (en) | Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer | |
| Serilmez et al. | CAN LYVE-1 MOLECULE BE A DIAGNOSTIC BIOMARKER IN PATIENTS WITH ADVANCED LUNG CANCER? |